PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Mercaptopurine→

Mercaptopurine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
50-44-2
Molecular formula
C5H4N4S
Molecular weight
152.18 g/mol
Drug class
Purine antimetabolitethiopurine immunosuppressant and antineoplastic agent
Mechanism of action
Converted intracellularly to thioguanine nucleotides and other active metabolites that interfere with purine nucleotide synthesis and incorporation into DNA and RNA, suppressing proliferation of rapidly dividing lymphoid cells.
Indications / reported uses
  • Treatment of acute lymphoblastic leukaemia (ALL) as part of combination chemotherapy, including maintenance regimens; dose and use are specialist-directed and depend on TPMT/NUDT15 status and blood-count monitoring

Sources: US DailyMed — Mercaptopurine tablets/oral suspension · NLM MeSH — Mercaptopurine · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Mercaptopurine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mercaptopurine Permitted Daily Exposure (PDE) report (the Mercaptopurine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mercaptopurine Occupational Exposure Limit (OEL) report (the Mercaptopurine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.